Protara Therapeutics Valuation
| TARA Stock | USD 4.50 0.02 0.44% |
At this time, the company appears to be overvalued. Protara Therapeutics holds a recent Real Value of $3.77 per share. The prevailing price of the company is $4.5. Our model determines the value of Protara Therapeutics from analyzing the company fundamentals such as Shares Owned By Institutions of 51.10 %, return on equity of -0.46, and Shares Outstanding of 34.76 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Protara Therapeutics' valuation include:
Overvalued
Today
Please note that Protara Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Protara Therapeutics is based on 3 months time horizon. Increasing Protara Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Protara Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Protara Stock. However, Protara Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.5 | Real 3.77 | Target 28.0 | Hype 4.5 | Naive 4.94 |
The real value of Protara Stock, also known as its intrinsic value, is the underlying worth of Protara Therapeutics Company, which is reflected in its stock price. It is based on Protara Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Protara Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Protara Therapeutics helps investors to forecast how Protara stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Protara Therapeutics more accurately as focusing exclusively on Protara Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Protara Therapeutics' intrinsic value based on its ongoing forecasts of Protara Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Protara Therapeutics' closest peers. If more than one evaluation category is relevant for Protara Therapeutics we suggest using both methods to arrive at a better estimate.
Protara Therapeutics Cash |
|
Protara Valuation Trend
Comparing Protara Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Protara Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Protara Therapeutics Total Value Analysis
Protara Therapeutics is at this time projected to have valuation of 79.65 M with market capitalization of 156.41 M, debt of 5.47 M, and cash on hands of 98.46 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Protara Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
79.65 M | 156.41 M | 5.47 M | 98.46 M |
Protara Therapeutics Asset Utilization
One of the ways to look at asset utilization of Protara is to check how much profit was generated for every dollar of assets it reports. Protara Therapeutics holds a negative application of assets of -0.28 pct., losing $0.002811 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Protara Therapeutics shows how discouraging it operates for each dollar spent on its assets.Protara Therapeutics Ownership Allocation
Protara Therapeutics owns a total of 34.76 Million outstanding shares. Over half of Protara Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Protara Therapeutics Profitability Analysis
Net Loss for the year was (40.42 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Protara Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Protara Therapeutics and how it compares across the competition.
About Protara Therapeutics Valuation
The stock valuation mechanism determines Protara Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Protara Therapeutics. We calculate exposure to Protara Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Protara Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -306.9 K | -291.6 K | |
| Pretax Profit Margin | (1.02) | (1.07) | |
| Operating Profit Margin | (2.31) | (2.43) | |
| Net Loss | (1.02) | (1.07) |
Protara Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 11.3 M |
Protara Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Protara Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Protara we look at many different elements of the entity such as Protara's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Protara Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Protara Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Protara Therapeutics' worth.Complementary Tools for Protara Stock analysis
When running Protara Therapeutics' price analysis, check to measure Protara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protara Therapeutics is operating at the current time. Most of Protara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protara Therapeutics' price. Additionally, you may evaluate how the addition of Protara Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Correlations Find global opportunities by holding instruments from different markets |